Conditions: Lung Cancer
Keywords: Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 69
Healthy volunteers: no

Brief summary:
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.

Detailed description:
Upon determination of eligibility all patients will receive:

* Docetaxel + Gemcitabine + Cetuximab

Arms:
arm 1: Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).

Interventions: intervention 1: Gemcitabine intervention 2: Docetaxel intervention 3: Cetuximab
Intervention descriptions: intervention 1: 1000mg/m2 30min IV, Day 1 \& 8 intervention 2: 30mg/m2, 30min IV, day 1 \& 8 intervention 3: 100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15

Protocol document: